BIONEWS
One dose of rapamycin temporarily improved autism-like brain and behavior changes in adult mice whose mothers had been exposed to inflammation during pregnancy, researchers at UCLA Health report in Nature Communications. The effect showed up within roughly two hours, did not survive repeat dosing, and was measured in a preclinical mouse model: rapamycin itself, the UCLA team writes, is not a candidate human autism therapy.
The single dose worked by dialing down activity in a brain signaling pathway called mTOR. Rapamycin is an immunosuppressant long used in transplant medicine; its mTOR-suppressing action has been linked in prior animal work to autism-related brain changes. In the new study, one injection lowered neuronal overactivity, reduced seizure susceptibility, and brought patterns of brain network organization back toward typical ranges. Repetitive behaviors and sensory over-responsivity also improved. A 2024 preprint from the same lab describes the same maternal-inflammation model and mechanism that the new paper now extends into adulthood.
The acute response is the part that breaks with prior work. Earlier mouse studies on mTOR and autism used chronic dosing; the new study found that one dose, not sustained treatment, was enough to bring several measures back toward control levels. First author Janel Le Belle, a neuroscientist in UCLA's Department of Neurosurgery, frames the result as a sign that the adult brain may retain the capacity for functional normalization even when the structural origins of the changes are not corrected. The reframing target is a long-standing working assumption in the field: that interventions must land in early development to matter. This study, taken at face value inside its mouse model, puts that assumption under empirical pressure rather than leaving it as a default.
The result carries three constraints. Rapamycin is an immunosuppressant, and the researchers flag that repeated dosing in their mice lost efficacy and carried toxicity risk. The autism-like traits were produced in one specific way, maternal inflammation rather than genetic models or human subjects, and the improvements were temporary. The cleanest interpretation: mTOR is now a tractable adult-stage target to study, not a treatment that is around the corner.
If the mTOR lever holds up under further work, the practical interest shifts to compounds that can engage the same pathway without rapamycin's toxicity ceiling, and to questions about which brain circuits carry the response. The paper is the original signal; a GEN News re-report carried the trade-publication version. The lab's stated next step, per the UCLA release, is to map which brain circuits carry the response and to test how long the acute window actually lasts. The wider question hanging over the field is whether the same mTOR pathway, probed with a different drug and a cleaner safety profile, behaves the same way outside this mouse model.